Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial
Dahlgren et al. conduct an open-label phase 2 trial of a full-spectrum, high-cannabidiol product in 14 patients with moderate-to-severe anxiety. Anxiety is significantly reduced and the drug well-tolerated with no serious adverse events.
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-022-00202-8 |